CDK4 and prostate carcinoma: A study by Eroğlu et al. [32] found antiproliferative action of FA in prostate cancer cells (PC-3 and LNCaP cells), which showed by elevating the gene expressions of ATR, RB1, ATM, CDKN1A, TP53, E2F4, and CDKN1B and reducing the gene expressions of CCND1, CDK2, CCND2, CCND3, CDK4, and CDK6 in PC-3 cells [32].